☰

Philip S. Boonstra, Ph.D. - Publications

Affiliations: 
2012 Biostatistics University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Biostatistics Biology
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Boonstra PS, Owen DR, Kang J. Shrinkage priors for isotonic probability vectors and binary data modeling, with applications to dose-response modeling. Pharmaceutical Statistics. PMID 38400582 DOI: 10.1002/pst.2372  0.318
2022 Hinton T, Karnak D, Tang M, Jiang R, Luo Y, Boonstra P, Sun Y, Nancarrow DJ, Sandford E, Ray P, Maurino C, Matuszak M, Schipper MJ, Green MD, Yanik GA, et al. Improved prediction of radiation pneumonitis by combining biological and radiobiological parameters using a data-driven Bayesian network analysis. Translational Oncology. 21: 101428. PMID 35460942 DOI: 10.1016/j.tranon.2022.101428  0.515
2022 Li P, Taylor JMG, Boonstra PS, Lawrence TS, Schipper MJ. Utility based approach in individualized optimal dose selection using machine learning methods. Statistics in Medicine. PMID 35343595 DOI: 10.1002/sim.9396  0.522
2021 Owen DR, Sun Y, Boonstra PS, McFarlane M, Viglianti BL, Balter JM, El Naqa I, Schipper MJ, Schonewolf CA, Ten Haken RK, Kong FS, Jolly S, Matuszak MM. Investigating the SPECT Dose-Function Metrics Associated With Radiation-Induced Lung Toxicity Risk in Patients With Non-small Cell Lung Cancer Undergoing Radiation Therapy. Advances in Radiation Oncology. 6: 100666. PMID 33817412 DOI: 10.1016/j.adro.2021.100666  0.537
2020 Bankhead A, McMaster T, Wang Y, Boonstra PS, Palmbos PL. TP63 isoform expression is linked with distinct clinical outcomes in cancer. Ebiomedicine. 51: 102561. PMID 31927310 DOI: 10.1016/J.Ebiom.2019.11.022  0.318
2019 Chase EC, Boonstra PS. Accounting for established predictors with the multistep elastic net. Statistics in Medicine. PMID 31313344 DOI: 10.1002/Sim.8313  0.325
2019 Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, ... Boonstra PS, et al. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. British Journal of Haematology. PMID 31044423 DOI: 10.1111/Bjh.15923  0.324
2019 Ye JC, Boonstra PS, Boyer DF, Anderson LD, Lipe BC, Kin A, Campagnaro EL, Pianko MJ, Talpaz M. A Phase 2 Study with Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma with Upfront Daratumumab-Based Therapy Blood. 134: 3191-3191. DOI: 10.1182/Blood-2019-132204  0.333
2018 Boonstra PS, Barbaro RP. Incorporating historical models with adaptive Bayesian updates. Biostatistics (Oxford, England). PMID 30247557 DOI: 10.1093/Biostatistics/Kxy053  0.313
2018 Menghrajani K, Boonstra PS, Mercer JA, Perkins C, Gowin KL, Weber AA, Mesa R, Gotlib JR, Wang L, Singer JW, Talpaz M. Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leukemia & Lymphoma. 1-7. PMID 30234400 DOI: 10.1080/10428194.2018.1509315  0.329
2018 Ma VT, Boonstra PS, Menghrajani K, Perkins C, Gowin KL, Mesa RA, Gotlib JR, Talpaz M. Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clinical Lymphoma, Myeloma & Leukemia. PMID 29574002 DOI: 10.1016/J.Clml.2018.02.019  0.302
2018 Alsawah F, Merrill SA, Bockenstedt PL, Campagnaro EL, Devata S, Gitlin SD, Kaminski MS, Cusick AM, Phillips TJ, Sood SL, Talpaz M, Quiery AT, Boonstra PS, Ahmed AZ, Wilcox RA. Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study Blood. 132: 1119-1119. DOI: 10.1182/Blood-2018-99-116854  0.329
2017 Hawkins PG, Boonstra PS, Hobson ST, Hayman JA, Ten Haken RK, Matuszak MM, Stanton P, Kalemkerian GP, Lawrence TS, Schipper MJ, Kong FS, Jolly S. Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels. Translational Oncology. 11: 102-108. PMID 29220828 DOI: 10.1016/J.Tranon.2017.11.005  0.597
2017 Hawkins PG, Boonstra PS, Hobson ST, Hearn JWD, Hayman JA, Ten Haken RK, Matuszak MM, Stanton P, Kalemkerian GP, Ramnath N, Lawrence TS, Schipper MJ, Spring Kong FM, Jolly S. Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28947099 DOI: 10.1016/J.Radonc.2017.09.005  0.578
2017 Boonstra PS, Braun TM, Taylor JM, Kidwell KM, Bellile EL, Daignault S, Zhao L, Griffith KA, Lawrence TS, Kalemkerian GP, Schipper MJ. Statistical controversies in cancer research: Building the bridge to phase II: efficacy estimation in dose-expansion cohorts. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28200082 DOI: 10.1093/Annonc/Mdx045  0.348
2017 Geer M, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Roberts E, ... Boonstra PS, et al. Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States Blood. 130: 377-377. DOI: 10.1182/Blood.V130.Suppl_1.377.377  0.318
2017 Garmezy B, Boonstra PS, Kandarpa M, Talpaz M. The Relationship between Cause of Death in Myelofibrosis and the Dynamic International Prognostic Scoring System Blood. 130: 2929-2929. DOI: 10.1182/Blood.V130.Suppl_1.2929.2929  0.3
2017 Menghrajani K, Boonstra P, Perkins C, Gowin K, Weber A, Mesa R, Gotlib J, Wang L, Singer J, Talpaz M. Models to Predict Response to JAK-inhibitor Therapy in Patients with Myelofibrosis Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.190  0.311
2016 Soni PD, Boonstra PS, Schipper MJ, Bazzi L, Dess RT, Matuszak MM, Kong FM, Hayman JA, Ten Haken RK, Lawrence TS, Kalemkerian GP, Jolly S. Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28161553 DOI: 10.1016/J.Ijrobp.2017.01.191  0.576
2016 Hawkins PG, Boonstra PS, Ten Haken RK, Matuszak MM, Kong FS, Lawrence TS, Schipper MJ, Jolly S. MINI01.13: Prediction of Lung Toxicity in the Definitive Radiotherapy of Non-Small Cell Lung Cancer using Clinical, Dosimetric and Biologic Factors: Topic: Radiation Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S264-S265. PMID 27969461 DOI: 10.1016/J.Jtho.2016.09.028  0.564
2016 Boonstra PS, Taylor JM, Smolska-Ciszewska B, Behrendt K, Dworzecki T, Gawkowska-Suwinska M, Bialas B, Suwinski R. Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. The British Journal of Radiology. 20150957. PMID 26903392 DOI: 10.1259/Bjr.20150957  0.312
2016 Menghrajani K, Boonstra PS, Perkins C, Gowin KL, Mesa RA, Gotlib JR, Talpaz M. A Predictive Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers and a Large Industry-Based Cohort Blood. 128: 4270-4270. DOI: 10.1182/Blood.V128.22.4270.4270  0.353
2015 Boonstra PS, Shen J, Taylor JM, Braun TM, Griffith KA, Daignault S, Kalemkerian GP, Lawrence TS, Schipper MJ. A statistical evaluation of dose expansion cohorts in phase I clinical trials. Journal of the National Cancer Institute. 107. PMID 25710960 DOI: 10.1093/Jnci/Dju429  0.544
2015 Menghrajani K, Boonstra PS, Weber A, Perkins C, Gowin K, Nguyen H, Mesa R, Gotlib JR, Talpaz M. To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.128  0.349
2014 Boonstra PS, Taylor JM, Mukherjee B. Increasing efficiency for estimating treatment-biomarker interactions with historical data. Statistical Methods in Medical Research. PMID 24855118 DOI: 10.1177/0962280214535370  0.301
2014 Boonstra PS, Bondarenko I, Park SK, Vokonas PS, Mukherjee B. Propensity score-based diagnostics for categorical response regression models. Statistics in Medicine. 33: 455-69. PMID 23934948 DOI: 10.1002/Sim.5940  0.31
2014 Kamal M, Boonstra PS, Weber AA, Perkins C, Gowin KL, Nguyen H(, Mesa R, Gotlib JR, Talpaz M. A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers Blood. 124: 1842-1842. DOI: 10.1182/Blood.V124.21.1842.1842  0.383
2013 Boonstra PS, Mukherjee B, Taylor JM. BAYESIAN SHRINKAGE METHODS FOR PARTIALLY OBSERVED DATA WITH MANY PREDICTORS. The Annals of Applied Statistics. 7: 2272-2292. PMID 24436727 DOI: 10.1214/13-Aoas668  0.341
2013 Boonstra PS, Taylor JM, Mukherjee B. Incorporating auxiliary information for improved prediction in high-dimensional datasets: an ensemble of shrinkage approaches. Biostatistics (Oxford, England). 14: 259-72. PMID 23087411 DOI: 10.1093/Biostatistics/Kxs036  0.302
2011 Boonstra PS, Mukherjee B, Taylor JM, Nilbert M, Moreno V, Gruber SB. Bayesian modeling for genetic anticipation in presence of mutational heterogeneity: a case study in Lynch syndrome. Biometrics. 67: 1627-37. PMID 21627626 DOI: 10.1111/J.1541-0420.2011.01607.X  0.314
Show low-probability matches.